These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 17253974)

  • 1. Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma.
    Hutchings M; Loft A; Hansen M; Berthelsen AK; Specht L
    Eur J Haematol; 2007 Mar; 78(3):206-12. PubMed ID: 17253974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of 18F-fluoro-2-deoxyglucose positron emission tomography on treatment strategy and radiotherapy planning for stage I-II Hodgkin disease: a prospective multicenter study.
    Pommier P; Dussart S; Girinsky T; Chabaud S; Lagrange JL; Nguyen TD; Beckendorff V; D'Hombres A; Artignan X; Bondiau PY; Carrie C; Giammarile F
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):823-8. PubMed ID: 20452732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of FDG-PET in the definition of involved-field radiation therapy and management for pediatric Hodgkin's lymphoma.
    Robertson VL; Anderson CS; Keller FG; Halkar R; Goodman M; Marcus RB; Esiashvili N
    Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):324-32. PubMed ID: 20646867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of PET-CT on involved field radiotherapy design for pediatric Hodgkin lymphoma.
    Paulino AC; Margolin J; Dreyer Z; Teh BS; Chiang S
    Pediatr Blood Cancer; 2012 Jun; 58(6):860-4. PubMed ID: 21826784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy.
    Sher DJ; Mauch PM; Van Den Abbeele A; LaCasce AS; Czerminski J; Ng AK
    Ann Oncol; 2009 Nov; 20(11):1848-53. PubMed ID: 19541793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies.
    Terezakis SA; Hunt MA; Kowalski A; McCann P; Schmidtlein CR; Reiner A; Gönen M; Kirov AS; Gonzales AM; Schöder H; Yahalom J
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):615-22. PubMed ID: 20933343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of FDG-PET in the implementation of involved-node radiation therapy for Hodgkin lymphoma patients.
    Girinsky T; Aupérin A; Ribrag V; Elleuch M; Fermé C; Bonniaud G; Ruelle C; Alberini JL; Celebic A; Edeline V
    Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):1047-1052. PubMed ID: 25035208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting?
    Girinsky T; Ghalibafian M; Bonniaud G; Bayla A; Magne N; Ferreira I; Lumbroso J
    Radiother Oncol; 2007 Nov; 85(2):178-86. PubMed ID: 17719110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coregistration of prechemotherapy PET-CT for planning pediatric Hodgkin's disease radiotherapy significantly diminishes interobserver variability of clinical target volume definition.
    Metwally H; Courbon F; David I; Filleron T; Blouet A; Rives M; Izar F; Zerdoud S; Plat G; Vial J; Robert A; Laprie A
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(3):793-9. PubMed ID: 20615626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk- and response-adapted strategies for the management of Hodgkin lymphoma.
    Remer M; Johnson PW
    Chin Clin Oncol; 2015 Mar; 4(1):13. PubMed ID: 25841720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of standardized uptake value thresholding for target volume delineation in pediatric Hodgkin lymphoma.
    Walker AJ; Chirindel A; Hobbs RF; Huynh-Le MP; Moore JA; Cho SY; Terezakis SA
    Pract Radiat Oncol; 2015; 5(4):219-27. PubMed ID: 26146182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
    Bradley J; Thorstad WL; Mutic S; Miller TR; Dehdashti F; Siegel BA; Bosch W; Bertrand RJ
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):78-86. PubMed ID: 15093902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer.
    Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1432-41. PubMed ID: 16125870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
    Specht L
    Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: preliminary results of a prospective study.
    Paolini R; Rampin L; Rodella E; Ramazzina E; Banti E; Al-Nahhas A; Rubello D
    Nucl Med Rev Cent East Eur; 2007; 10(2):87-90. PubMed ID: 18228212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consistency of FDG-PET accuracy and cost-effectiveness in initial staging of patients with Hodgkin lymphoma across jurisdictions.
    Cerci JJ; Trindade E; Buccheri V; Fanti S; Coutinho AM; Zanoni L; Linardi CC; Celli M; Delbeke D; Pracchia LF; Pitela FA; Soares J; Zinzani PL; Meneghetti JC
    Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):314-20. PubMed ID: 21816369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of CT and 18F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma.
    Moureau-Zabotto L; Touboul E; Lerouge D; Deniaud-Alexandre E; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Kerrou K; Montravers F; Keraudy K; Tiret E; Gendre JP; Grange JD; Houry S; Talbot JN
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):340-5. PubMed ID: 16168829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDG-PET in the clinical management of Hodgkin lymphoma.
    Hutchings M; Eigtved AI; Specht L
    Crit Rev Oncol Hematol; 2004 Oct; 52(1):19-32. PubMed ID: 15363464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of FDG PET/CT on delineation of the gross tumor volume for radiation planning in non-small-cell lung cancer.
    Spratt DE; Diaz R; McElmurray J; Csiki I; Duggan D; Lu B; Delbeke D
    Clin Nucl Med; 2010 Apr; 35(4):237-43. PubMed ID: 20305410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy?
    Hutchings M
    Hematol Oncol Clin North Am; 2014 Feb; 28(1):87-103. PubMed ID: 24287070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.